169 related articles for article (PubMed ID: 2478245)
21. Molsidomine prevents post-ischaemic ventricular fibrillation in dogs.
Cano JP; Guillen JC; Jouve R; Langlet F; Puddu PE; Rolland PH; Serradimigni A
Br J Pharmacol; 1986 Aug; 88(4):779-89. PubMed ID: 3755634
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells.
Cone J; Wang S; Tandon N; Fong M; Sun B; Sakurai K; Yoshitake M; Kambayashi J; Liu Y
J Cardiovasc Pharmacol; 1999 Oct; 34(4):497-504. PubMed ID: 10511123
[TBL] [Abstract][Full Text] [Related]
23. Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction.
Lynch JJ; Uprichard AC; Frye JW; Driscoll EM; Kitzen JM; Lucchesi BR
J Cardiovasc Pharmacol; 1989 Oct; 14(4):585-97. PubMed ID: 2478772
[TBL] [Abstract][Full Text] [Related]
24. Role of cyclic GMP-inhibitable phosphodiesterase and nitric oxide in the beta adrenoceptor control of renin secretion.
Chiu T; Reid IA
J Pharmacol Exp Ther; 1996 Aug; 278(2):793-9. PubMed ID: 8768733
[TBL] [Abstract][Full Text] [Related]
25. Treating metabolic impairment and myocardial stunning with phosphodiesterase inhibitor type III, milrinone, administered prior to coronary artery occlusion in the presence of calcium channel blockade in pigs.
Sidi A; Muehlschlegel JD; Kirby DS; Lobato EB
Ann Card Anaesth; 2007 Jan; 10(1):34-41. PubMed ID: 17455406
[TBL] [Abstract][Full Text] [Related]
26. Myocardial effects of cyclic AMP phosphodiesterase inhibition are dampened in thyroxine-induced cardiac hypertrophy.
Straznicka M; Leone RJ; Scholz PM; Weiss HR
J Surg Res; 1998 Apr; 76(1):61-6. PubMed ID: 9695741
[TBL] [Abstract][Full Text] [Related]
27. The effect of SK&F 95654, a novel phosphodiesterase inhibitor, on cardiovascular, respiratory and platelet function.
Murray KJ; Eden RJ; Dolan JS; Grimsditch DC; Stutchbury CA; Patel B; Knowles A; Worby A; Lynham JA; Coates WJ
Br J Pharmacol; 1992 Oct; 107(2):463-70. PubMed ID: 1422592
[TBL] [Abstract][Full Text] [Related]
28. Effect of milrinone on thromboxane A2 synthesis, cAMP phosphodiesterase and 45Ca2+ uptake by human platelets.
Jeremy JY; Gill J; Mikhailidis D
Eur J Pharmacol; 1993 Mar; 245(1):67-73. PubMed ID: 7682964
[TBL] [Abstract][Full Text] [Related]
29. Anesthetized rabbit as a model for ischemia- and reperfusion-induced arrhythmias: effects of quinidine and bretylium.
Coker SJ
J Pharmacol Methods; 1989 Jul; 21(4):263-79. PubMed ID: 2755145
[TBL] [Abstract][Full Text] [Related]
30. Ocular effects of topical administration of the phosphodiesterase III inhibitor milrinone in rabbits and cats.
Lee KC; Silver PJ; Bode DC; Gherezghiher T
Methods Find Exp Clin Pharmacol; 1993 Oct; 15(8):527-34. PubMed ID: 8309316
[TBL] [Abstract][Full Text] [Related]
31. Milrinone inhibits sympathetic-mediated tachycardia by a postjunctional action independent of cyclic AMP.
Minatoguchi S; Majewski H
J Cardiovasc Pharmacol; 1991 Jul; 18(1):127-36. PubMed ID: 1719281
[TBL] [Abstract][Full Text] [Related]
32. Treatment of milrinone-associated tachycardia with beta-blockers.
Alhashemi JA; Hooper J
Can J Anaesth; 1998 Jan; 45(1):67-70. PubMed ID: 9466032
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure.
Sato N; Asai K; Okumura S; Takagi G; Shannon RP; Fujita-Yamaguchi Y; Ishikawa Y; Vatner SF; Vatner DE
Am J Physiol; 1999 May; 276(5):H1699-705. PubMed ID: 10330256
[TBL] [Abstract][Full Text] [Related]
34. Preload-dependent hemodynamic effects of milrinone in moderate heart failure.
Remme WJ; van Hoogenhuyze DC; Kruijssen HA; Pieper PG; Bruggeling WA
Cardiology; 1992; 80(2):132-42. PubMed ID: 1611632
[TBL] [Abstract][Full Text] [Related]
35. Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs.
Vandeplassche GM; Hermans CF; de Chaffoy de Courcelles DR; D'Aubioul JA; Wouters LJ; De Clerck FF
J Cardiovasc Pharmacol; 1992 May; 19(5):714-22. PubMed ID: 1381769
[TBL] [Abstract][Full Text] [Related]
36. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs.
Papp JG; Pollesello P; Varró AF; Végh AS
J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):129-35. PubMed ID: 16891290
[TBL] [Abstract][Full Text] [Related]
37. The mechanism of action of calcium antagonists on arrhythmias in early myocardial ischaemia: studies with nifedipine and DHM9.
Curtis MJ; Walker MJ
Br J Pharmacol; 1988 Aug; 94(4):1275-86. PubMed ID: 3207985
[TBL] [Abstract][Full Text] [Related]
38. Milrinone. A preliminary review of its pharmacological properties and therapeutic use.
Young RA; Ward A
Drugs; 1988 Aug; 36(2):158-92. PubMed ID: 3053125
[TBL] [Abstract][Full Text] [Related]
39. [Hemodynamic effects of milrinone in the treatment of cardiac insufficiency after heart surgery with extracorporeal circulation].
Lançon JP; Caillard B; Obadia JF; Pillet M; Leblanc-Beaufils C; Le Bloch Y
Arch Mal Coeur Vaiss; 1991 Nov; 84(11):1575-9. PubMed ID: 1763924
[TBL] [Abstract][Full Text] [Related]
40. Acute effects of milrinone on the electrocardiogram and the cardiac hemodynamics of rats with pressure overload-induced congestive heart failure.
Desjardins S; Cauchy MJ
Arch Int Pharmacodyn Ther; 1989; 301():182-99. PubMed ID: 2624514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
